Janus Henderson Group
CRL icon

Janus Henderson Group’s Charles River Laboratories CRL Stock Holding History

Janus Henderson Group’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.81M Sell
22,078
-122
-0.5% -$22.6K ﹤0.01% 1043
2025
Q4 		$4.43M Sell
22,200
-1,455
-6% -$264K ﹤0.01% 986
2025
Q3 		$3.7M Hold
23,655
– – ﹤0.01% 1042
2025
Q2 		$3.59M Sell
23,655
-548
-2% -$73.1K ﹤0.01% 1030
2025
Q1 		$3.76M Sell
24,203
-32,085
-57% -$5.38M ﹤0.01% 983
2024
Q4 		$10.4M Buy
56,288
+10,270
+22% +$1.98M 0.01% 720
2024
Q3 		$9.06M Buy
46,018
+3,268
+8% +$679K ﹤0.01% 708
2024
Q2 		$8.83M Sell
42,750
-3,821
-8% -$866K ﹤0.01% 694
2024
Q1 		$12.6M Sell
46,571
-32,964
-41% -$7.87M 0.01% 646
2023
Q4 		$18.8M Buy
79,535
+8,555
+12% +$1.68M 0.01% 564
2023
Q3 		$13.9M Sell
70,980
-17,369
-20% -$3.57M 0.01% 605
2023
Q2 		$18.6M Sell
88,349
-25,713
-23% -$5.12M 0.01% 571
2023
Q1 		$23M Buy
114,062
+45,383
+66% +$10.3M 0.02% 544
2022
Q4 		$15M Buy
68,679
+64,508
+1,547% +$14.1M 0.01% 627
2022
Q3 		$822K Sell
4,171
-680
-14% -$147K ﹤0.01% 1739
2022
Q2 		$1.04M Sell
4,851
-9,822
-67% -$2.4M ﹤0.01% 1299
2022
Q1 		$4.17M Buy
14,673
+8,421
+135% +$2.6M ﹤0.01% 1051
2021
Q4 		$2.36M Buy
6,252
+127
+2% +$49.3K ﹤0.01% 1225
2021
Q3 		$2.53M Sell
6,125
-11,489
-65% -$4.77M ﹤0.01% 1207
2021
Q2 		$6.51M Buy
+17,614
New +$5.88M ﹤0.01% 1008
2020
Q1 		– Sell
-12,399
Closed -$1.89M – 1319
2019
Q4 		$1.89M Sell
12,399
-20,968
-63% -$2.9M ﹤0.01% 1170
2019
Q3 		$4.42M Sell
33,367
-37,309
-53% -$5M ﹤0.01% 1071
2019
Q2 		$10M Buy
70,676
+20,293
+40% +$2.75M 0.01% 947
2019
Q1 		$7.32M Sell
50,383
-30,682
-38% -$4.03M ﹤0.01% 947
2018
Q4 		$9.18M Buy
81,065
+30,565
+61% +$3.83M 0.01% 902
2018
Q3 		$6.79M Buy
50,500
+5,100
+11% +$629K ﹤0.01% 981
2018
Q2 		$5.1M Sell
45,400
-10,700
-19% -$1.16M ﹤0.01% 1021
2018
Q1 		$5.99M Buy
56,100
+5,000
+10% +$539K ﹤0.01% 979
2017
Q4 		$5.59M Buy
51,100
+46,900
+1,117% +$5.1M ﹤0.01% 964
2017
Q3 		$454K Buy
+4,200
New +$431K ﹤0.01% 1233

Other funds holding CRL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Janus Henderson Group's CRL Position: Q1 2026 in Review

Janus Henderson Group reduced its Charles River Laboratories (CRL) stake by 0.55% in Q1 2026, selling an estimated $22.6K and leaving 22,078 shares worth $3.81M. The position accounts for ﹤0.01% of the portfolio, ranked #1043.

Janus Henderson Group first reported a position in CRL in Q3 2017 and has held it in 30 quarters since. The position peaked at $23M in Q1 2023. 557 funds tracked by Wall St. Rank hold CRL as of Q1 2026.

  • Janus Henderson Group held 22,078 shares of Charles River Laboratories worth $3.81M as of Q1 2026.
  • Janus Henderson Group sold 122 Charles River Laboratories shares in Q1 2026, an estimated $22.6K.
  • Charles River Laboratories made up ﹤0.01% of Janus Henderson Group's portfolio in Q1 2026, its #1043 holding.
  • Janus Henderson Group first reported a position in Charles River Laboratories in Q3 2017 and has held it in 30 quarters since.
  • Janus Henderson Group's Charles River Laboratories position peaked at $23M in Q1 2023.
  • 557 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.

Based on Janus Henderson Group's 13F filing for Q1 2026, filed 15 May 2026.